Trevi Therapeutics (TRVI) Interest Coverage Ratio (2018 - 2024)
Trevi Therapeutics' quarterly Interest Coverage Ratio came in at 12243.0 in Q4 2024, down 448.21% year-on-year from 3515.94 in Q1 2024, and up 13.09% quarter-over-quarter from 14087.0 in Q3 2024.
Trevi Therapeutics has reported Interest Coverage Ratio for 6 years, with the latest figure at 12243.0 in Q4 2024.
- For the quarter ending Q4 2024, Interest Coverage Ratio fell 448.21% year-over-year to 12243.0; the trailing twelve-month figure through Sep 2025 stood at 50232.0 (down 629.28% YoY), and the FY2024 full-year result was 12881.0, down 14746.77% from the prior year.
- Interest Coverage Ratio for Q4 2024 stood at 12243.0, up from 14087.0 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 10.0 in Q4 2021, with the low at 14087.0 in Q3 2024.
- Average Interest Coverage Ratio over 5 years is 3173.74, with a median of 31.29 recorded in 2020.
- Year-over-year, Interest Coverage Ratio soared 66.48% in 2021 and sank 36265.01% in 2024.
- Tracing TRVI's Interest Coverage Ratio over 5 years: stood at 29.85 in 2020, then soared by 66.48% to 10.0 in 2021, then plunged by 142.87% to 24.3 in 2022, then tumbled by 9091.99% to 2233.25 in 2023, then plunged by 448.21% to 12243.0 in 2024.
- The last three Interest Coverage Ratio figures came in at 12243.0 (Q4 2024), 14087.0 (Q3 2024), and 13289.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -12,243.00 |
| Sep 30, 2024 | -14,087.00 |
| Jun 30, 2024 | -13,289.00 |
| Mar 31, 2024 | -11,906.00 |
| Dec 31, 2023 | -2,233.25 |
| Sep 30, 2023 | -3,015.00 |
| Jun 30, 2023 | -54.78 |
| Mar 31, 2023 | -32.74 |
| Dec 31, 2022 | -24.30 |
| Sep 30, 2022 | -28.78 |
| Jun 30, 2022 | -26.51 |
| Mar 31, 2022 | -23.26 |
| Dec 31, 2021 | -10.00 |
| Sep 30, 2021 | -22.93 |
| Jun 30, 2021 | -24.45 |
| Mar 31, 2021 | -27.51 |
| Dec 31, 2020 | -29.85 |
| Sep 30, 2020 | -48.95 |
| Jun 30, 2018 | -85.88 |
| Mar 31, 2018 | -25.54 |